Your browser doesn't support javascript.
loading
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome.
Iltar, Utku; Alhan, Fadime Nurcan; Vural, Ece; Atas, Ünal; Sözel, Hasan; Dogan, Ömer; Boduroglu, Ahmet; Yücel, Orhan Kemal; Salim, Ozan; Ündar, Levent.
Afiliação
  • Iltar U; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Alhan FN; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Vural E; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Atas Ü; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Sözel H; Department of Internal Medicine, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Dogan Ö; Department of Radiology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Boduroglu A; Department of Pathology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Yücel OK; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Salim O; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
  • Ündar L; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, 37502Akdeniz University, Antalya, Turkey.
J Oncol Pharm Pract ; 28(2): 500-503, 2022 Mar.
Article em En | MEDLINE | ID: mdl-34636655
ABSTRACT

INTRODUCTION:

Hypomethylating agents have confirmed efficacy for myelodysplastic syndrome and acute myeloid leukemia and are widely used. Although arthralgia is common side effect associated with hypomethylating agents, arthritis has not been reported previously. CASE REPORT We present the first recorded patient with arthritis after azacitidine treatment. The patient we presented here had severe cytopenias requiring transfusion with erythrocyte and platelet suspensions, and a complete hematological response was obtained for myelodysplastic syndrome after three cycles of azacitidine (AZA) treatment. However, interestingly, after each AZA treatment cycle, the patient had recurrent attacks of arthritis. MANAGEMENT AND

OUTCOMES:

The episodes of arthritis were possibly acute flares of pre-existing crystal-induced arthritis, as exhibited with azacitidine treatments and were managed effectively with nonsteroidal anti-inflammatory drugs.

DISCUSSION:

Because it is a rare condition, clinicians should not overlook AZA as a possible cause of arthritis exacerbations when arthritis of unknown etiology develops in patients treated with AZA.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Síndromes Mielodisplásicas / Leucemia Mieloide Aguda Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Síndromes Mielodisplásicas / Leucemia Mieloide Aguda Idioma: En Ano de publicação: 2022 Tipo de documento: Article